SpyGlass Pharma, Inc. (SGP) Income Statement
SGP 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsSGP revenue and net income
SGP growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
SGP quarterly EPS vs estimates
SpyGlass Pharma beat the analyst EPS estimate in 1 of the last 3 quarters. Next report: November 5, 2026 (estimate $-0.66).
SGP income statement
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of revenue | $612,000 | — | — |
| Gross profit | −$612,000 | — | — |
| Research & development | $28.6M | $20.0M | $10.0M |
| Sales, general & admin | $12.2M | $7.1M | $4.3M |
| Total operating expenses | $40.8M | $27.1M | $14.2M |
| Operating income | −$41.4M | −$27.1M | −$14.2M |
| Interest income | $3.1M | $1.3M | $911,375 |
| Income before taxes | −$39.9M | −$29.2M | −$13.3M |
| Net income | −$39.9M | −$29.2M | −$13.3M |
| EBITDA | −$39.3M | −$26.8M | −$14.1M |
| EPS (diluted) | −$0.38 | −$0.91 | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $341,000 | $318,000 | $216,726 | — | — | — | — |
| Gross profit | −$341,000 | −$318,000 | −$216,726 | — | — | — | — |
| Research & development | $10.6M | $8.2M | $7.7M | $8.1M | $7.3M | $6.1M | $5.7M |
| Sales, general & admin | $11.0M | $6.9M | $5.9M | $3.0M | $2.0M | $1.4M | $2.0M |
| Total operating expenses | $21.6M | $15.1M | $13.4M | $11.1M | $9.3M | $7.4M | $7.8M |
| Operating income | −$22.0M | −$15.4M | −$13.6M | −$11.1M | −$9.3M | −$7.4M | −$7.8M |
| Interest income | $2.1M | $1.6M | $1.1M | $1.3M | $622,000 | $126,000 | $207,181 |
| Income before taxes | −$19.9M | −$13.8M | −$12.6M | −$9.8M | −$8.7M | −$8.8M | −$8.4M |
| Net income | −$19.9M | −$13.8M | −$12.6M | −$9.8M | −$8.7M | −$8.8M | −$8.4M |
| EBITDA | −$21.6M | −$13.5M | −$12.3M | −$11.0M | −$9.2M | — | — |
| EPS (diluted) | −$0.59 | −$0.69 | −$0.38 | — | — | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in SGP's financial statements (latest annual report filed March 26, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
SGP financial results
SpyGlass Pharma reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $39.9 million. Diluted earnings per share came to −$0.38.
See the SGP stock overview for the latest quote and news, or the SGP chart for price history and technical indicators.
SGP income statement FAQ
Does SpyGlass Pharma have revenue?
SpyGlass Pharma reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is SpyGlass Pharma profitable?
No. SpyGlass Pharma reported a net loss of $39.9 million in fiscal 2025.
How much does SpyGlass Pharma spend on research and development?
SpyGlass Pharma spent $28.6 million on research and development in fiscal 2025.
What are SpyGlass Pharma's earnings per share?
SpyGlass Pharma earned $-0.38 per diluted share in fiscal 2025, compared with $-0.91 a year earlier.
When will SpyGlass Pharma report its next earnings?
SpyGlass Pharma is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 after the market closes.
When does SpyGlass Pharma's fiscal year end?
SpyGlass Pharma's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 26, 2026.